Abstracts tagged "Allopurinol"

Abstract Number: 2109 • 2015 ACR/ARHP Annual Meeting
Racial Disparities in the Risk of Hospitalized Severe Allopurinol Hypersensitivity Syndrome – a US Nationwide Study (2009-2011)
Na Lu¹, Sharan K. Rai², Jeewoong Choi³ and Hyon K. Choi¹, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ³Massachusetts College of Pharmacy and Health Sciences, Boston, MA
Background/Purpose: Allopurinol is the leading choice of urate-lowering therapy for gout (>95% of treated cases); however, it is associated with the rare but potentially fatal…
Abstract Number: 2112 • 2015 ACR/ARHP Annual Meeting
Analysis of Gout Subjects Receiving Lesinurad and Allopurinol Combination Therapy By Baseline Renal Function
Kenneth G. Saag¹, Thomas Bardin², Alexander So^3,4, Puja Khanna⁵, Chris Storgard⁶, Scott Baumgartner⁷, Maple Fung⁷, Nihar Bhakta⁷, Scott Adler⁸, Jeff Kopicko⁷ and Michael A. Becker⁹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Lariboisière Hospital, Paris, France, ³Rheumatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, ⁴CHU Vaudois, University of Lausanne, Lausanne, Switzerland, ⁵Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ⁶4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁷Ardea Biosciences, Inc., San Diego, CA, ⁸AstraZeneca Pharmaceuticals, Wilmington, DE, ⁹University of Chicago, Chicago, IL
Background/Purpose: Two randomized, double-blind, placebo-controlled Phase III clinical trials showed that lesinurad (200 or 400 mg) when added to allopurinol (200-900 mg) significantly increased the…
Abstract Number: 2240 • 2015 ACR/ARHP Annual Meeting
Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate: A Study Using Large Intergrated National Health Network
Jasvinder A. Singh¹, Shuo Yang², S. Louis Bridges Jr.³ and Kenneth G. Saag⁴, ¹Birmingham VAMC, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To comprehensively assess patient, comorbidity, physician, system, health care access and disease factors associated with the ability to achieve and maintain target serum urate…
Abstract Number: 2342 • 2015 ACR/ARHP Annual Meeting
Uric Acid-Lowering Therapy Management Among Rural Veterans Affairs Primary Care Providers
Michael Darley¹, Grant W. Cannon² and Christopher Jackson³, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: ACR guidelines exist for the management of gout including the use of uric acid-lowering therapy. ACR guidelines recommend routine monitoring of uric acid levels…
Abstract Number: 2354 • 2015 ACR/ARHP Annual Meeting
The Safety and Efficacy of Lower Serum Urate Levels: A Pooled Analysis of Gout Subjects Receiving Lesinurad and Xanthine Oxidase Inhibitors
Robert Terkeltaub¹, Fernando Perez-Ruiz^2,3,4, Jeff Kopicko⁵, Maple Fung⁵, Scott Adler⁶, Chris Storgard⁷, Scott Baumgartner⁵ and Nicola Dalbeth⁸, ¹Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ²Rheumatology Division, Hospital Universitario Cruces, Barakaldo, Spain, ³BioCruces Health Research Institute, Baracaldo, Spain, ⁴Servicio de Reumatologia, Hospital De Cruces, Baracaldo, Spain, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶AstraZeneca Pharmaceuticals, Wilmington, DE, ⁷4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁸Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Previous studies have shown that long-term urate-lowering therapy (ULT) is required for improvements in gout flare frequency and tophi reduction, and that lower serum…
Abstract Number: 2357 • 2015 ACR/ARHP Annual Meeting
Xanthine Oxidase Inhibitors for the Prevention of Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Markus Bredemeier¹, Matheus Augusto Eisenreich¹, Lediane Moreira Lopes¹, André Luis Bittencourt Morsch², Fernando da Silva Stein², Rui d'Avila² and Guilherme Gomes Dias Campos¹, ¹Rheumatology, Hospital Nossa Senhora da Conceição - Grupo Hospital Conceição, Porto Alegre, Brazil, ²Internal Medicine, Hospital Nossa Senhora da Conceição - Grupo Hospital Conceição, Porto Alegre, Brazil
Background/Purpose: There is evidence suggesting that high levels of uric acid represent an independent cardiovascular risk factor and that the use of xanthine oxidase inhibitors…
Abstract Number: 179 • 2014 ACR/ARHP Annual Meeting
Effect of Allopurinol on All-Cause Mortality in Adults with Incident Gout: Propensity Score Matched Landmark Analysis
Chang-Fu Kuo^1,2, Matthew J. Grainge³, Christian Mallen⁴, Weiya Zhang¹ and Michael Doherty⁵, ¹Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ²Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taipei, Taiwan, ³Division of Epidemiology and Public Health, School of Community Health Sciences,, University of Nottingham, Nottingham, United Kingdom, ⁴Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, ⁵Division of Rheumatology, Orthopedics and Dermatology, University of Nottingham, Nottingham, United Kingdom
Background/Purpose Although current guidelines recommend allopurinol as a first-line urate-lowering treatment for gout patients, whether the balance of potential benefits and risks can translate to…
Abstract Number: 177 • 2014 ACR/ARHP Annual Meeting
Increase in Thyroid Stimulating Hormone (TSH) Levels in Patients with Gout Treated with Inhibitors of Xanthine-Oxido-Reductase
Fernando Perez-Ruiz^1,2, Ana M. Herrero-Beites^1,3, M. Angeles Aniel-Quiroga⁴ and Sandra P Chinchilla⁵, ¹BioCruces Health Research Institute, Baracaldo, Spain, ²Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ³Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain, ⁴Biochemistry, Hospital Universitario Cruces, Baracaldo, Spain, ⁵Rheumatology, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: Increase in thyroid stimulating hormone (TSH) levels over upper normal limit has been reported in a small percentage of patients treated with febuxostat, but…
Abstract Number: 170 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Skin Reactions with Gout Medications: An Analysis of VA Databases
Jasvinder A. Singh¹, Shuo Yang² and Jeff Foster³, ¹University of Alabama and VA Medical Center, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Dermatologic side effects to use of gout treatments are concerning to patients. The goal of the study was to assess the risk of occurrence…
Abstract Number: 166 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Gout Attack Recurrence during Urate-Lowering Allopurinol Treatment
Myeong Jae Yoon¹, Ji Ae Yang², Sang Hyun Joo¹, Sang Jin Lee¹, Jin Young Moon¹, Hyun Mi Kwon¹, Dong Jin Ko¹, Yeong Wook Song¹ and Eun Bong Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose Gout is a recurrent inflammatory arthritis caused by crystal deposition of monosodium urate, which can be prevented urate-lowering agents such as allopurinol. However, gout…
Abstract Number: 164 • 2014 ACR/ARHP Annual Meeting
Gouty Patients with History of Adverse Reaction to Allopurinol Are Not at Higher Risk of Reaction to Febuxostat
Thomas Bardin¹, René-Marc Flipo², Pascal Richette³ and Pierre Clerson⁴, ¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ²rheumatology, Rene Salengro hospital, Lille, France, ³INSERM 1132, Université Paris-Diderot, Hôpital Lariboisière, Paris, France, ⁴Orgametrie, Roubaix, France
Background/Purpose Allopurinol is the standard drug for urate-lowering management of gout. Allopurinol is safe in most patients. The most frequent side effects are minor cutaneous…
Abstract Number: 163 • 2014 ACR/ARHP Annual Meeting
Is the Rate of Skin Reactions to Febuxostat Increased in Patients with a History of Skin Intolerance to Allopurinol? a Retrospective, Hospital-Based Study Involving 101 Patients Consecutively Treated with Allopurinol and Febuxostat
Thomas Bardin¹, Gérard Chales², Tristan Pascart³, René-Marc Flipo⁴, Jean-Claude Roujeau⁵, Aurélie Delayen⁶ and Pierre Clerson⁷, ¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ²Dept of Rheumatology, CHR - Hopital Sud, Rennes, France, ³Rheumatology, Saint-Philibert Hospital, LOMME, France, ⁴rheumatology, Rene Salengro hospital, Lille, France, ⁵Dermatology, University Paris Est, Créteil, France, ⁶Orgamétrie biostatistiques, Roubaix, France, ⁷Orgametrie, Roubaix, France
Background/Purpose: Allopurinol can lead to skin toxicity. Minor skin reactions are reported in 2-4% of patients and life threatening severe cutaneous reactions (SCARs) in 0.1-0.4%.…
Abstract Number: 46 • 2014 ACR/ARHP Annual Meeting
Xanthine Oxidase Inhibitors and Risk of Type 2 Diabetes in Patients with Gout
Seoyoung C. Kim¹, John D. Seeger², Jun Liu³ and Daniel H. Solomon⁴, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ³Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hyperuricemia and gout are associated with an increased risk of type 2 diabetes (T2D). Xanthine oxidase inhibitors (XOI), allopurinol and febuxostat, are the main…
Abstract Number: L10 • 2014 ACR/ARHP Annual Meeting
Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Two Phase III Clinical Trials: Combination Study of Lesinurad in Allopurinol Standard of Care Inadequate Responders (CLEAR 1 and 2)
Kenneth G. Saag¹, Scott Adler², Nihar Bhakta³, Maple Fung³, Jeff Kopicko³, Chris Storgard³ and Thomas Bardin⁴, ¹Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ²AstraZeneca Pharmaceuticals, Wilmington, DE, ³Ardea Biosciences, Inc., San Diego, CA, ⁴Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France
Background/Purpose: Inadequate response to allopurinol monotherapy is common. Lesinurad (RDEA594) is a selective uric acid reabsorption inhibitor (SURI) under investigation for treatment of gout in…
Abstract Number: 2121 • 2014 ACR/ARHP Annual Meeting
Real-World Cost Comparison of Urate Lowering Therapies in Patients with Gout and Moderate to Severe Chronic Kidney Disease
Ghaith Mitri¹, Eric Wittbrodt¹, Robin Turpin¹, Beni Tidwell² and Kathy Schulman², ¹Medical Affairs, Takeda Pharmaceuticals International, Deerfield, IL, ²Outcomes Research Solutions, Inc., Waltham, MA
Background/Purpose Gout flare prevention relies heavily on urate-lowering therapies (ULT) such as allopurinol (ALP) and febuxostat (FBX) but clinical decision-making in patients with moderate to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].